Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312572 | 0.94 | SIGMAR1 (0.42) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL1106443 | 0.91 | SIGMAR1 (0.32) | SIGMAR1HRH3ABCB1 | |
| SCHEMBL1106428 | 0.84 | ALDH1A1 (0.34) | HRH3CYP2D6KCNH2 | |
| SCHEMBL18032457 | 0.83 | L3MBTL3 (0.35) | HRH3CYP2D6ABCB1 | |
| SCHEMBL26419480 | 0.83 | ABCB1 (0.33) | SIGMAR1HRH3CYP2D6ABCB1 | |
| SCHEMBL23180455 | 0.82 | CHRM2 (0.35) | HRH3KCNH2 | |
| SCHEMBL24828001 | 0.82 | MEN1 (0.40) | — | |
| SCHEMBL18032444 | 0.82 | CYP2D6 (0.36) | SIGMAR1HRH3CYP2D6ABCB1 | |
| SCHEMBL18032450 | 0.82 | CYP2D6 (0.36) | SIGMAR1HRH3CYP2D6ABCB1 | |
| SCHEMBL18032453 | 0.82 | CYP2D6 (0.36) | SIGMAR1HRH3CYP2D6ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | SIGMAR1 442/4885HRH3 2327/4885CYP2D6 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.